Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Summarize this article with:
Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(23min)CommentsSummaryAbivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis.Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results.Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.Recent $700M+ capital raise extends cash runway into Q4 2027, supporting ongoing pivotal trials and strategic expansion opportunities. Dragos Condrea/iStock via Getty Images The last time I spoke about Abivax SA (ABVX) it was with respect to a Seeking Alpha article entitled "Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial CatalysThis article was written byTerry Chrisomalis14.48K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You